TAKEDA DEVELOPMENT CENTRE EUROPE LTD

Their core work

Takeda Development Centre Europe is the European R&D arm of Takeda Pharmaceutical Company, one of the world's largest biopharmaceutical firms. Within H2020, they contribute pharmaceutical industry expertise to large-scale public-private partnerships focused on real-world evidence generation, digital health endpoints, and disease stratification. Their role centers on bridging clinical drug development with patient-centered outcomes research, particularly in neurodegenerative diseases, hematological cancers, autoimmune disorders, and inflammatory conditions. They bring industry-grade clinical trial infrastructure, proprietary compound knowledge, and regulatory strategy experience to multi-stakeholder research consortia.

What they specialise in

How they've shifted over time

In their early H2020 period (2016–2017), Takeda focused on disease-specific data platforms and real-world evidence — projects like ROADMAP (Alzheimer's), HARMONY (hematology big data), and PREFER (patient preference data). From 2019 onward, their focus shifted decisively toward digital health tools, remote monitoring, and molecular-level disease understanding: projects like MOBILISE-D (digital mobility assessment), IDEA-FAST (digital endpoints for fatigue and sleep), 3TR (single-cell genomics for treatment response), and Trials@Home (decentralized trials). This evolution mirrors the broader pharma industry pivot from retrospective data collection toward prospective digital biomarkers and precision medicine.

Takeda is moving toward digital biomarkers, remote patient monitoring, and molecular stratification — future collaborators should bring capabilities in wearable sensors, computational biology, or decentralized trial design.

How they like to work

Takeda participates exclusively as a consortium partner, never as coordinator — consistent with large pharma's role in IMI and RIA projects where they contribute industry data, clinical expertise, and regulatory insight without leading the governance. With 355 unique partners across 27 countries, they operate as a high-connectivity hub in European health research networks. Their consistent presence in IMI-funded public-private partnerships (HARMONY, EBiSC2, RADAR-AD) signals they are a reliable, long-term industry partner comfortable in large consortia of 20+ members.

Takeda has collaborated with 355 distinct partners across 27 countries, making them one of the most broadly connected pharmaceutical companies in H2020 health research. Their network spans all major European research nations and includes universities, hospitals, regulatory bodies, SMEs, and other pharma companies through the IMI framework.

What sets them apart

As a top-10 global pharmaceutical company with a dedicated European development centre, Takeda brings a scale of clinical and regulatory expertise that few other H2020 participants can match. Their simultaneous involvement in neurology, oncology/hematology, and immunology projects makes them a rare cross-therapeutic partner within a single organization. For academic researchers, partnering with Takeda provides direct access to industry-grade drug development pipelines and real-world clinical data that are otherwise inaccessible.

Highlights from their portfolio

• 3TR
  Ambitious multi-year project (2019–2026) tackling molecular mechanisms of treatment non-response across autoimmune and inflammatory diseases using single-cell genomics and integrative multi-omics.
• HARMONY
  One of the largest hematology big data platforms in Europe, integrating real-life patient data across leukemia, lymphoma, and myeloma with a 6-year timeline (2017–2023).
• MOBILISE-D
  Pioneering digital mobility assessment as a regulatory-endorsed clinical endpoint across COPD, Parkinson's, MS, and hip fracture recovery — bridging wearable tech with pharma outcomes.